Evommune (EVMN) Capital Expenditures (2025 - 2026)
Evommune (EVMN) reported Capital Expenditures of $83000.0 for Q1 2026, up 186.46% on a QoQ basis from -$96000.0 in Q4 2025.
Evommune (EVMN) has 2 years of Capital Expenditures data on file, last reported at $83000.0 in Q1 2026.
- Quarterly Capital Expenditures changed N/A year-over-year to $83000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$13000.0 (changed N/A YoY) and the FY2025 annual result came in at $35000.0, down 60.23% from the prior year.
- Capital Expenditures rose to $83000.0 in Q1 2026 per EVMN's latest filing, from -$96000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $83000.0 in Q1 2026 and bottomed at -$96000.0 in Q4 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 133.40 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 230.60 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 21.83 Mn |
| 10 | Evommune | 744.11 Mn | 532.65 Mn | - | 83,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 83,000.00 |
| Mar 31, 2026 | 83,000.00 |
| Dec 31, 2025 | -96,000.00 |
| Dec 31, 2025 | -96,000.00 |